Hudson Bay Capital revealed 1,025,824 shares in Catalyst Pharmaceutical Partners, Inc. (CPRX) on October 31st, corresponding to a 4.15% passive stake. The firm reported 683,429 shares in CPRX in its last 13F filing, so this is a 50% expansion in its position. Hudson Bay Capital might enter at about $1.35 when CPRX is wavering throughout October. According to the 13G release, Hudson Bay Capital once had more than 5% stake in CPRX on or near October 28th. Now CPRX is trading at $1.04 after its public offering of common shares and warrants on Friday.
From Bloomberg Businessweek, Hudson Bay Capital Management is “an employee owned hedge fund sponsor. The firm invests in the public equity and hedging markets across the globe. It employs multi-strategy approach to make its investments. It was formerly known as Gerber Capital Management. Hudson Bay Capital was founded in 1997 and is based in New York City”.
Catalyst Pharmaceutical Partners, Inc. is a development-stage biopharmaceutical company. It focuses on the development and commercialization of prescription drugs for the central nervous system. The company mainly develops CPP-109 and CPP-115. The company was founded in 2002 and is based in Coral Gables, Florida.